retatrutide cons Diagram showing the mechanism of action of Retatrutide side effects: What to

While the underlying metabolic dysfunction persists and would likely return if medication stopped, the daily reality for these individuals resembles non-diabetic glucose metabolism

Retatrutide, a GIP/GLP-1/Glucagon receptor agonist (GGG tri-agonist) in development by Eli Lilly and Company, isnt on the market yet

That means even if youre taking a GLP-1 medication for diabetes or weight management, the bodys response, like insulin release, may be blunted

This is not unusual and reflects the complex interplay of slowed gastric emptying (which promotes constipation) and altered intestinal motility (which can trigger diarrhea)

GLP-1

JAMA 276 , 15801588 (1996)